- Home
- ADCT vs GLQ Comparison
ADCT vs GLQ Comparison
Compare ADCT & GLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- GLQ
- Stock Information
- Founded
- ADCT 2011
- GLQ 2005
- Country
- ADCT Switzerland
- GLQ United States
- Employees
- ADCT N/A
- GLQ N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- GLQ Finance/Investors Services
- Sector
- ADCT Health Care
- GLQ Finance
- Exchange
- ADCT Nasdaq
- GLQ Nasdaq
- Market Cap
- ADCT 127.9M
- GLQ 119.5M
- IPO Year
- ADCT 2020
- GLQ N/A
- Fundamental
- Price
- ADCT $1.28
- GLQ $6.49
- Analyst Decision
- ADCT Strong Buy
- GLQ
- Analyst Count
- ADCT 5
- GLQ 0
- Target Price
- ADCT $7.75
- GLQ N/A
- AVG Volume (30 Days)
- ADCT 235.3K
- GLQ 65.5K
- Earning Date
- ADCT 05-14-2025
- GLQ 01-01-0001
- Dividend Yield
- ADCT N/A
- GLQ 11.11%
- EPS Growth
- ADCT N/A
- GLQ N/A
- EPS
- ADCT N/A
- GLQ N/A
- Revenue
- ADCT $70,837,000.00
- GLQ N/A
- Revenue This Year
- ADCT $6.82
- GLQ N/A
- Revenue Next Year
- ADCT $18.56
- GLQ N/A
- P/E Ratio
- ADCT N/A
- GLQ N/A
- Revenue Growth
- ADCT 1.84
- GLQ N/A
- 52 Week Low
- ADCT $1.05
- GLQ $5.13
- 52 Week High
- ADCT $4.83
- GLQ $6.54
- Technical
- Relative Strength Index (RSI)
- ADCT 43.00
- GLQ 62.75
- Support Level
- ADCT $1.23
- GLQ $6.22
- Resistance Level
- ADCT $1.49
- GLQ $6.12
- Average True Range (ATR)
- ADCT 0.08
- GLQ 0.08
- MACD
- ADCT 0.00
- GLQ 0.05
- Stochastic Oscillator
- ADCT 25.00
- GLQ 87.84
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.